Table III.

Efficacy in the 1q21 subtype without other high‐risk chromosomal abnormalities (isolated 1q21).

	≥3 copies of gain(1q21)			Amplification with ≥4 copies of 1q21
	Isa‐Pd (n = 56)	Pd (n = 29)	P value	Isa‐Pd (n = 23)	Pd (n = 9)	P value
mPFS, mo[95% CI]	11·2 [6·5–13·3]	4·6 [2·3–7·9]		8·9 [3·7–12·3]	2·3 [0·1–NC]
	HR, 0·50 [0·28–0·88]			HR, 0·55 [0·21–1·43]
ORR, n (%)[95% CI]	30 (53·6)[0·4–0·7]	8 (27·6)[0·1–0·5]	0·0116	12 (52·2)[0·3–0·7]	1 (11·1)[<0·1–0·5]	0·0182
≥VGPR, n (%)[95% CI]	14 (25·0)[0·1–0·4]	1 (3·4)[<0·1–0·2]	0·0070	7 (30·4)[0·1–0·5]	0[NC]	0·0327

mPFS, median progression‐free survival; CI, confidence interval; ORR, overall response rate; VGPR, very good partial response; Isa, isatuximab; P, pomalidomide; d, dexamethasone; HR hazard ratio; NC, not calculated.

P values are from the unstratified one‐sided Cochran–Mantel–Haenszel test.